Amit Chaudhari MD (@NeuroIRdoc) header
Amit Chaudhari MD (@NeuroIRdoc) profile picture

Neurologist | Neurointensivist | Neurointerventionalist | 🧑‍⚕️👨‍🍼👑

Joined September 2016
Photo by Amit Chaudhari MD (@NeuroIRdoc)Photo by Amit Chaudhari MD (@NeuroIRdoc)Photo by Amit Chaudhari MD (@NeuroIRdoc)Photo by Amit Chaudhari MD (@NeuroIRdoc)Photo by Amit Chaudhari MD (@NeuroIRdoc)Photo by Amit Chaudhari MD (@NeuroIRdoc)Photo by Amit Chaudhari MD (@NeuroIRdoc)Photo by Amit Chaudhari MD (@NeuroIRdoc)Photo by Amit Chaudhari MD (@NeuroIRdoc)Photo by Amit Chaudhari MD (@NeuroIRdoc)
Amit Chaudhari MD retweeted
Dr. @oozaidat and Dr. @DanTonettiMD , discussing permanent vs non permanent endovascular treatment of migraine headaches #svin2026 @svinsociety – at Las Vegas, NV
1
6
14
804
Amit Chaudhari MD retweeted
🎉 Please join us in congratulating our newest Fellows of SVIN! • Jaydevisinh Dolia, MD, FSVIN @JayDoliaMD • Faheem Sheriff, MD, FSVIN @faheem_sheriff • Kaustubh Limaye, MD, PhD, FSVIN @kaustubhslimaye • Fazeel Siddiqui, MD, FSVIN @FMSiddiquiMD • Osman Kozak, MD, FSVIN • Sishir Mannava, MD, FSVIN @SishMannMD • Haralabos Zacharatos, DO, FSVIN @Neuroconsult 🔗 zurl.co/ecDkT #ALLIN #SVIN26 #svinannualmeeting #SVINFellows #vascularneurology #lasvegas #interventionalneurology
7
16
702
Amit Chaudhari MD retweeted
Just weeks after approval in China, asundexian is now FDA-approved, ushering in a new class of therapies for stroke prevention! A gratifying milestone after years of research and global collaboration. Congratulations to Bayer and the entire OCEANIC-STROKE team! @McmasterStroke
🚨The FDA has approved asundexian for secondary stroke prevention in patients with non-cardioembolic ischemic stroke or high-risk TIA.🚨 Our latest article explores the approval, featuring expert insights from recent interviews with @mike_sharma2 and @Ash_Shoamanesh on the OCEANIC-STROKE trial and the clinical implications. 📖Read more: ow.ly/W6Uy5105j8r Intended for healthcare professionals. #Stroke #FDAApproval #Neurology
2
15
2
52
3,671
Amit Chaudhari MD retweeted
Thrilled to announce that Insera’s CLEAR™ Aspiration System featuring #CyclicalAspiration has received U.S. #FDA 510(k) clearance for the peripheral vasculature. Thank you to our physicians, partners & the #MedTech community who made this possible. See => prn.to/4xPX8sA
4
3
15
1,186
Amit Chaudhari MD retweeted
🤔 Is 3 months of DAPT enough after flow diversion? In this multicenter registry analysis of 721 patients treated with Pipeline Shield, approximately 3 months of DAPT was not associated with increased ischemic complications compared with prolonged therapy. These findings suggest consideration of a shorter DAPT regimen in selected patients, although prospective validation is needed. 🧠 🔗 Read more at bit.ly/3WDkMeS
9
14
1,694
Amit Chaudhari MD retweeted
Pioneer of endovascular neurosurgery and innovator Dr. @oozaidat will be joining with most recent updates and cutting edge of the pivotal @SealTrial at the @brainconferenc1 in December! Must look forward to it #endovascular #aneurysm #stroke #brain
3
3
214
Amit Chaudhari MD retweeted
New JNIS | A coated flow diverter compatible with 0.017 inch microcatheters In this prospective multicenter study of the AUCURA flow diverter: 96.99% achieved successful occlusion at 12 months 95.49% achieved complete occlusion Major stroke or neurological death occurred in 1.40% A very interesting next-generation FD concept combining a low-profile delivery system, antithrombotic coating, and strong aneurysm occlusion results. đź”— bit.ly/47khyz6 #JNIS #FlowDiversion #Aneurysm #Neurointervention
7
21
2,393
Amit Chaudhari MD retweeted
In a recent @JNIS_BMJ study, @fdianamd et al evaluated adding rosuvastatin to aspirin to improve #aneurysm healing after flow diversion in a rabbit model. Here, Diana outlines key findings, signals that warrant caution, and where research should go next neuronewsinternational.com/c…
2
1
559
Amit Chaudhari MD retweeted
FIB-CAS Prospect is a collaborative, multi-site effort to answer an important clinical question in patients with ICAS and AF. One year in & more enrollments ahead. Grateful to every investigator and coordinator helping move the study forward đź§  #Stroke #ICAS #AtrialFibrillation
2
5
1
13
1,041
Amit Chaudhari MD retweeted
The HALF-IT score, novel simplified MRI-based score for selecting candidates for basilar artery mechanical thrombectomy @oozaidat @Mo_majali91 @NeuroIRdoc
New Research: The HALF-IT score: proposing a simplified mechanical thrombectomy triage tool for basilar artery occlusion www.​frontiersin.​org/articles/10.​3389/fneur.​2026.​1915436 #FrontiersIn #Neurology
2
1
166
Amit Chaudhari MD retweeted
And here's another meta-analysis yet again showing benefit (mRS 0-2) when giving TPA/TNK in the 4.5-24 hour window based on penumbral imaging. When is this going to become mainstream? Thrombolysis in the Delayed Treatment Window for Acute Ischemic Stroke: Updated Systematic Review and Meta-Analysis | @StrokeAHA_ASA ahajournals.org/doi/abs/10.1…
5
23
58
5,152
Amit Chaudhari MD retweeted
I am thrilled to share that the SPIDER-WEB study comparing carotid revasc vs. medical tx in patients with symptomatic carotid webs is complete. The results will be submitted to ISC 2027. We are grateful for the contributing sites. Do you think we have a winner? #stroke #ISC27
7
22
3
113
5,515
Amit Chaudhari MD retweeted
In the landmark CREST-2 study, revascularization did not influence cognition in patients with otherwise asymptomatic carotid stenosis. Read the key results: jwat.ch/4dfphlh
3
1
12
2,187
Mark your calendars for these important dates pertaining to #Match2027. Be sure not to miss the following ERAS submission dates, leading up to the #neurointerventional match!
2
5
508
Amit Chaudhari MD retweeted
SEAL Commercial update - India, here we go! SEAL has received regulatory approval in India! Thank you to our local partners and the Galaxy team for making this milestone possible. #SEAL #GalaxyTherapeutics #India
2
3
196
Amit Chaudhari MD retweeted
Super large bore aspiration catheters (SLACs) in stroke thrombectomy: 📊 A systematic review of 532 patients found ~92% thrombus access, ~55% first-pass effect, and ~81% final near-complete reperfusion, with low complication rates. 🔬 Larger prospective trials are still needed to define their optimal role. Read more here: bit.ly/4hFDTMk
1
9
32
2,835
Amit Chaudhari MD retweeted
A tremendous honor to work with everyone with collaborative expertise here at USC!
Incredible neurovascular program @KeckMedicineUSC featuring #neurosurgery, #neurology & #radiology. David L our superstar #stroke #neurologist starts things off by casting a vision of an NV Operating System. #Brilliant @NeimanHPI @SNISinfo #Neuro
1
5
502
Amit Chaudhari MD retweeted
“A man who fights technology is a man who lost”. Technology is changing how we deliver care. @UofLHealth is proud to partner w/ @penumbrainc, allowing us to bring the most complex, comprehensive, & cutting edge cerebrovascular care in Ohio Valley Region. uoflhealth.org/news/first-in…
1
5
201